Free FPGEE Practice Test Questions and Answers (2026)

Lyophilization (freeze-drying) involves freezing a pharmaceutical solution and removing water by sublimation under reduced pressure. Option D is incorrect because the eutectic temperature is defined as the lowest temperature at which a liquid mixture of two or more components can exist at equilibrium, rather than simply being the initial freezing point of the drug solution. Freezing of the liquid solution begins at the liquidus temperature, whereas complete solidification occurs below the eutectic temperature (or glass transition temperature for amorphous systems). During lyophilization, heat-labile solutes maintain stability, water sublimes directly from ice, and solute molecules commonly consolidate into a porous, amorphous glass structure to facilitate rapid reconstitution.

A. Minimal loss of activity in heat labile materials is a true statement because processing occurs at very low temperatures.

B. The liquid must be frozen below the eutectic temperature to ensure complete solidification without unfrozen liquid pockets during sublimation.

C. Solutes in lyophilized formulations frequently form an amorphous glass matrix, which provides rapid dissolution upon reconstitution.

E. Water is removed by sublimation during primary drying, directly converting frozen ice into water vapor.

1. Tang, X. C., & Pikal, M. J. (2004). Design of freeze-drying processes for pharmaceuticals: Practical advice. Pharmaceutical Research, 21(2), 191-200. https://doi.org/10.1023/B:PHAM.0000016276.70110.8a

2. Felton, L. A. (2012). Remington: The Science and Practice of Pharmacy (22nd ed., pp. 1145-1150). Pharmaceutical Press.

Metronidazole is a synthetic nitroimidazole antimicrobial agent with potent activity exclusively against anaerobic bacteria and certain protozoal pathogens, such as Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia. It acts through reduction of its nitro group by electron transport proteins in anaerobic organisms, generating cytotoxic free radicals that disrupt DNA. Metronidazole possesses no activity against fungal organisms. Conversely, Amphotericin B and Nystatin are polyene antifungal agents that bind ergosterol in fungal cell membranes; Griseofulvin is an antifungal that inhibits fungal mitosis; and Clotrimazole is an imidazole antifungal that inhibits ergosterol biosynthesis. Thus, metronidazole is correctly identified as the non-antifungal agent among the options listed.

A. Amphotericin B is a polyene antifungal agent used to treat systemic fungal infections.

C. Griseofulvin is an oral antifungal drug used specifically for dermatophytic fungal infections of skin, hair, and nails.

D. Nystatin is a polyene antifungal drug used locally for Candida infections.

E. Clotrimazole is a topical azole antifungal indicated for superficial fungal infections.

1. Katzung, B. G. (2021). Basic & Clinical Pharmacology (15th ed., Chapter 48: Antifungal Agents, pp. 881-890 & Chapter 52: Antiprotozoal Drugs, pp. 945-952). McGraw-Hill.

2. Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2018). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed., Chapter 57: Antifungal Agents, pp. 1087-1098). McGraw-Hill.

3. https://doi.org/10.1128/CMR.00028-18

Cephalosporins are beta-lactam antibiotics that bactericidally inhibit bacterial cell wall synthesis. Their structural similarity to the D-alanyl-D-alanine peptide terminus allows them to competitively bind to penicillin-binding proteins (PBPs), specifically transpeptidases. Transpeptidases are essential enzymes responsible for cross-linking the peptidoglycan chains that maintain the structural integrity and rigidity of the bacterial cell wall. By inhibiting transpeptidase activity and activation of autolytic enzymes within the cell wall, cephalosporins prevent final peptidoglycan cross-linking. This weakens the cell wall, causing osmotic instability, cell lysis, and ultimate bacterial death. Because eukaryotic human cells lack a peptidoglycan cell wall, this targeted mechanism provides selective toxicity against susceptible Gram-positive and Gram-negative bacterial species during active cell growth.

Option A: Protein synthesis inhibition is the mechanism of action for aminoglycosides, tetracyclines, and macrolides, not cephalosporin beta-lactam antibiotics.

Option C: Inhibition of essential metabolite synthesis (such as folate synthesis) is the mechanism of action of sulfonamides and trimethoprim.

Option D: Altering cell membrane permeability and disruption is characteristic of lipopeptide and polypeptide antibiotics like daptomycin and polymyxins.

Option E: Inhibition of genetic information translation involves ribosomal targeting antibiotics like aminoglycosides or oxazolidinones, rather than cell wall-active agents.

1. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13th Ed., Chapter 56: Penicillins, Cephalosporins, and Other β-Lactam Antibiotics, pp. 1023-1038.

2. Foye's Principles of Medicinal Chemistry, 7th Ed., Chapter 33: β-Lactam Antibiotics, pp. 1045-1060.

3. MIT OpenCourseWare, Health Sciences and Technology, HST.151: Principles of Pharmacology, "Cell Wall Inhibitors".

Propylthiouracil (PTU) is a thiourea-derivative antithyroid medication that inhibits the enzyme thyroid peroxidase, thereby blocking the organification of iodide and coupling of iodotyrosines in the synthesis of thyroid hormones (thyroxine and triiodothyronine). Additionally, PTU inhibits the peripheral conversion of T4 to T3. It is clinically indicated for the management of hyperthyroidism, thyrotoxicosis, thyroid storm, and as a preoperative preparation prior to thyroidectomy or radioactive iodine (131-I) therapy to render the patient euthyroid and prevent hyperthyroid crisis. Controlling thyroid hormone levels prior to radioactive iodine treatment minimizes the risk of radiation-induced release of stored thyroid hormones into circulation, making PTU an effective agent for adjunctive preparation in thyrotoxicosis management.

A. Glaucoma: Glaucoma is treated using topical prostaglandin analogs, beta-blockers (e.g., timolol), or carbonic anhydrase inhibitors to decrease intraocular pressure, not antithyroid drugs.

B. Migraine prophylaxis: Migraine prophylaxis utilizes agents such as propranolol, topiramate, amitriptyline, or CGRP antagonists; PTU has no pharmacologic role in migraine management.

D. Severe recurrent ventricular tachyarrhythmias: Recurrent ventricular tachyarrhythmias require antiarrhythmic drugs such as amiodarone, lidocaine, or sotalol, whereas PTU specifically targets thyroid hormone synthesis.

E. Broad spectrum antibacterial agent: PTU is a synthetic antithyroid thionamide, possessing no antibacterial properties or activity against bacterial pathogens.

- Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition. Chapter 43: Thyroid and Antithyroid Drugs. McGraw Hill, 2023.

- Katzung's Basic & Clinical Pharmacology, 15th Edition. Chapter 38: Thyroid & Antithyroid Drugs, pp. 687-692. McGraw Hill, 2021.

- Ross DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. https://doi.org/10.1089/thy.2016.0229

Gonorrhea is a sexually transmitted infection caused by the Gram-negative diplococcus Neisseria gonorrhoeae. Standard antimicrobial pharmacotherapy includes third-generation cephalosporins, such as parenteral ceftriaxone and oral cefixime, which inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins. Historically and pharmacologically, fluoroquinolones such as ciprofloxacin were also indicated and widely prescribed for gonococcal infections due to their potent inhibition of bacterial DNA gyrase and topoisomerase IV. Although resistance patterns have shifted clinical guidelines toward preferred ceftriaxone regimens, all three agents (cefixime, ceftriaxone, and ciprofloxacin) possess pharmacological activity and regulatory indications for treating Neisseria gonorrhoeae infections. Therefore, all listed statements (I, II, and III) represent valid treatment options, making option E correct.

A: Statement I is valid, but statements II and III are also established anti-gonococcal therapeutic agents.

B: Statement III is valid, but statements I and II are primary cephalosporins used against gonorrhea.

C: Statements I and II are valid, but ciprofloxacin (statement III) is also an anti-gonococcal antimicrobial agent.

D: Statements II and III are valid, but cefixime (statement I) is also an effective anti-gonococcal cephalosporin.

- Centers for Disease Control and Prevention (CDC). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1-187.

- Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13th ed. McGraw-Hill, Chapter 56: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics.

- Workowski, K. A., & Bachmann, L. H. (2022). Sexually Transmitted Infections Treatment Guidelines. Clinical Infectious Diseases, 74(Suppl 2), S89-S94. https://doi.org/10.1093/cid/ciac022

Penicillin V (phenoxymethylpenicillin) is an oral beta-lactam antibiotic characterized by acid stability, allowing it to withstand gastric acidity better than Penicillin G, though it remains sensitive to degradation by bacterial beta-lactamases. Penicillins exhibit a short biological half-life (30 to 60 minutes) due to rapid renal clearance, which involves both glomerular filtration and active tubular secretion. Co-administration of probenecid competitively blocks the organic anion transporters responsible for active renal tubular secretion of penicillins. By delaying renal clearance, probenecid elevates plasma concentrations and prolongs the biological half-life, effectively increasing the therapeutic duration and activity of Penicillin V. Thus, statements I, II, and III are correct.

Option A: Choice A is incorrect because options II and III are also valid descriptions of Penicillin V clearance and probenecid interaction.

Option B: Choice B is incorrect because options I and II are also correct statements regarding Penicillin V stability and elimination pathways.

Option C: Choice C is incorrect because option III is also correct; probenecid decreases tubular elimination, effectively enhancing penicillin activity.

Option D: Choice D is incorrect because option I is also a correct description regarding the acid stability and beta-lactamase susceptibility of Penicillin V.

1. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13th Ed., Chapter 56: Penicillins, Cephalosporins, and Other β-Lactam Antibiotics, pp. 1025-1030.

2. Remington: The Science and Practice of Pharmacy, 23rd Ed., Chapter 48: Antimicrobial Agents, pp. 915-925.

3. Cunningham, R. F., et al. (1981). Clinical pharmacokinetics of probenecid. Clinical Pharmacokinetics, 6(2), 135-151. DOI: https://doi.org/10.2165/00003088-198106020-00004

Flunisolide is a synthetic fluorinated corticosteroid used primarily in the management of allergic rhinitis and asthma. Corticosteroids exert their anti-inflammatory actions by binding to intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene transcription. A primary mechanism includes the upregulation of lipocortin-1 (annexin A1) production. Lipocortin-1 directly inhibits phospholipase A2, the enzyme responsible for cleaving membrane phospholipids to liberate arachidonic acid. By blocking phospholipase A2 activity, flunisolide effectively prevents the downstream cascade leading to the synthesis of potent inflammatory mediators, including prostaglandins, leukotrienes, and thromboxanes, thereby attenuating airway inflammation, vascular permeability, and mucosal edema.

A: Fluoroquinolone antibiotics inhibit bacterial DNA gyrase (topoisomerase II) to disrupt bacterial DNA replication, which is unrelated to the anti-inflammatory action of glucocorticoids.

B: Phosphodiesterase inhibition is characteristic of agents like theophylline or sildenafil, which elevate intracellular cyclic nucleotide levels rather than acting through glucocorticoid receptor signaling pathways.

D: Beta-2 adrenergic agonists, such as albuterol, stimulate G-protein-coupled beta-2 receptors on bronchial smooth muscle to cause bronchodilation without directly inhibiting inflammatory phospholipase enzymes.

E: Histamine H2 receptor antagonists, such as ranitidine, competitively block H2 receptors located on gastric parietal cells to suppress gastric acid output.

1. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill Education; 2017: p. 605-610.

2. Barnes PJ. Glucocorticoids. Chem Immunol Allergy. 2014;100:311-316. DOI: https://doi.org/10.1159/000358852

3. DailyMed. Flunisolide Nasal Solution FDA Label. US National Library of Medicine. Section 12.1 Clinical Pharmacology. https://dailymed.nlm.nih.gov

Phenelzine is a hydrazine derivative that acts as a potent, non-selective, and irreversible inhibitor of monoamine oxidase (MAO-A and MAO-B). Because of severe dietary restrictions regarding tyramine intake and potential drug-drug interactions, phenelzine is typically reserved as a second- or third-line agent that may work when other antidepressants fail to produce an adequate clinical response. Furthermore, phenelzine irreversibly inactivates the monoamine oxidase enzyme, and clinical antidepressant efficacy correlates with achieving greater than 80% inhibition of platelet monoamine oxidase activity. Despite its long-lasting pharmacodynamic effects requiring weeks for enzyme turnover, phenelzine itself possesses a relatively short plasma elimination half-life.

A. Phenelzine inhibits monoamine oxidase to increase synaptic monoamines; nitric oxide (NO) generation is not involved in its primary mechanism of action.

B. Phenelzine is administered orally and does not cause neuromuscular paralysis; rapid IV infusion causing paralysis is characteristic of aminoglycosides or neuromuscular blockers.

D. Phenelzine has a short plasma elimination half-life (1.5 to 4 hours), though its pharmacodynamic inhibition of MAO persists for up to two weeks.

- Katzung, B. G. (2021). Basic & Clinical Pharmacology (15th ed.). McGraw-Hill, Chapter 30: Antidepressant Agents, pp. 531-550.

- Robinson, D. S., et al. (1978). Relation of clinical response to monoamine oxidase inhibition by phenelzine. Archives of General Psychiatry, 35(5), 629–635. https://doi.org/10.1001/archpsyc.1978.01770290111011

Codeine (3-O-methylmorphine) possesses functional groups capable of undergoing direct Phase II metabolic conjugation. Specifically, UDP-glucuronosyltransferases (predominantly UGT2B7) directly conjugate the hydroxyl group at the C-6 position of codeine to yield codeine-6-glucuronide, which constitutes a major pathway (approx. 80%) of codeine elimination. Additionally, sulfotransferases (SULTs) can directly catalyze sulfoconjugation at the C-6 hydroxyl position of codeine to produce codeine-6-sulfate. Glutathione S-transferases require electrophilic functional groups or reactive epoxide intermediates and do not directly act on intact codeine. Because both UDP-glucuronosyltransferase (A) and sulfotransferase (B) directly act on codeine, Option D is the correct answer.

A. This option is incomplete because sulfotransferase also directly conjugates codeine at the C-6 position.

B. This option is incomplete because UDP-glucuronosyltransferase also directly conjugates codeine at the C-6 position.

C. Glutathione S-transferase does not directly conjugate codeine because codeine lacks electrophilic, reactive sites required for GST activity.

E. This option is incorrect because glutathione transferase (C) does not directly act on codeine.

1. Armstrong, S. C., & Cozza, K. L. (2003). Pharmacokinetics of opioids. Psychosomatics, 44(6), 515–523. https://doi.org/10.1176/appi.psy.44.6.515

2. Court, M. H., Krishnaswamy, S., Koukouritaki, S. B., et al. (2003). Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase UGT2B7 in human liver microsomes. Drug Metabolism and Disposition, 31(9), 1125–1133. https://doi.org/10.1124/dmd.31.9.1125

3. Foye, W. O., Lemke, T. L., & Williams, D. A. (2013). Foye's Principles of Medicinal Chemistry (7th ed., Chapter 20: Opioid Analgesics, pp. 653-678). Lippincott Williams & Wilkins.

Penicillins undergo various pharmacokinetic and pharmacodynamic interactions with multiple substances. Antacids decrease gastric acidity and alter the absorption rate of certain oral penicillins. Food decreases the oral bioavailability of penicillins such as ampicillin and penicillin V by delaying gastric emptying and promoting acid degradation. Probenecid competitively inhibits the renal tubular secretion of penicillins, thereby elevating and prolonging their serum drug concentrations. Aminoglycosides exhibit significant interactions with penicillins, including synergistic bactericidal effects in vivo and direct chemical inactivation when mixed together in the same intravenous container or infusion line. Therefore, antacids, food, probenecid, and aminoglycosides can all interfere with the regular absorption, disposition, or pharmacological effect of penicillins, making all options correct.

A. Antacids alter gastric pH and GI absorption of penicillins, but options B, C, and D are also correct interactions, making E the comprehensive choice.

B. Food delays gastric emptying and reduces penicillins' bioavailability, but options A, C, and D are also valid interactions, making E the correct overall option.

C. Probenecid competes for renal tubular secretion, altering penicillin elimination, but options A, B, and D also interfere, making E the most complete answer.

D. Aminoglycosides undergo physicochemical inactivation in vitro and synergistic pharmacodynamic interactions in vivo with penicillins, but A, B, and C are also correct.

1. Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2018). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed., pp. 1023-1028). McGraw-Hill Education.

2. Katzung, B. G. (2021). Basic & Clinical Pharmacology (15th ed., Section VIII: Chemotherapeutic Drugs, Chapter 43: Beta-Lactam & Other Cell Wall- & Membrane-Active Antibiotics, pp. 793-802). McGraw-Hill Education.

3. https://doi.org/10.1093/cid/cir1020